Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-05-18 | Dec-31-17 | Dec-31-16 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 8-K | 10-K | 10-K |
| Revenues: |
| Performance Enzymes | 126.6 | 90.5 | 48.1 | 58.2 | 47.1 | | 42.3 | |
| Novel Biotherapeutics | 12.0 | 14.2 | 21.0 | 10.3 | 13.5 | | 7.7 | |
| Total revenues [+] | 138.6 | 104.8 | 69.1 | 68.5 | 60.6 | 60.6 | 50.0 | 48.8 |
| Royalties | | | | | | 30.0 | | |
| Products | | | | | | 25.6 | | |
| Revenue growth [+] | 32.3% | 51.7% | 0.9% | 13.0% | 21.1% | | 2.4% | 16.8% |
| Performance Enzymes | 39.9% | 88.2% | -17.3% | 23.5% | 11.2% | | | |
| Novel Biotherapeutics | -15.9% | -32.0% | 103.4% | -23.8% | 75.8% | | | |
| Cost of goods sold | 38.0 | 22.2 | 13.7 | 15.6 | 12.6 | 12.6 | 14.3 | 9.8 |
| Gross profit | 100.6 | 82.5 | 55.3 | 52.8 | 48.0 | 48.0 | 35.7 | 39.1 |
| Gross margin | 72.6% | 78.8% | 80.1% | 77.2% | 79.2% | 79.2% | 71.4% | 80.0% |
| Selling, general and administrative | 52.2 | 49.3 | 35.0 | 31.5 | 29.3 | 59.3 | 29.0 | 25.4 |
| Research and development | 80.1 | 55.9 | 44.2 | 33.9 | 30.0 | | 29.7 | 22.2 |
| EBITDA [+] | -26.3 | -19.6 | -22.0 | -11.0 | -10.1 | | -21.9 | -4.0 |
| EBITDA growth | 34.4% | -10.9% | 100.1% | 8.2% | -53.7% | | 445.7% | 70.2% |
| EBITDA margin | -19.0% | -18.7% | -31.8% | -16.0% | -16.7% | -18.6% | -43.8% | -8.2% |
| Depreciation | 5.4 | 3.1 | 2.0 | 1.6 | 1.1 | | 1.0 | 1.7 |
| EBITA | -31.7 | -22.7 | -23.9 | -12.5 | -11.3 | -11.3 | -23.0 | -5.8 |
| EBITA margin | -22.9% | -21.7% | -34.6% | -18.3% | -18.6% | -18.6% | -45.9% | -11.8% |
| Amortization of intangibles | | | | | | | | 2.8 |
| EBIT [+] | -31.7 | -22.7 | -23.9 | -12.5 | -11.3 | -11.3 | -23.0 | -8.6 |
| EBIT growth | 39.7% | -5.1% | 90.6% | 11.1% | -50.8% | | 168.2% | 10.2% |
| EBIT margin | -22.9% | -21.7% | -34.6% | -18.3% | -18.6% | -18.6% | -45.9% | -17.5% |
| Non-recurring items | 3.2 | | | | | | | |
| Interest income | 1.4 | 0.5 | 0.4 | 1.3 | 0.7 | 0.7 | 0.1 | 0.1 |
| Interest income | 1.4 | 0.5 | 0.4 | 1.3 | 0.7 | 0.7 | 0.1 | 0.1 |
| Other income (expense), net | 0.1 | 1.1 | -0.2 | -0.7 | -0.3 | -0.3 | -0.1 | -0.1 |
| Pre-tax income | -33.3 | -21.1 | -23.7 | -11.9 | -10.9 | -10.9 | -22.9 | -8.6 |
| Income taxes | 0.3 | 0.2 | 0.3 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 |
| Tax rate | | | | | 0.3% | 0.3% | | 0.5% |
| Net income | -33.6 | -21.3 | -24.0 | -11.9 | -10.9 | -10.9 | -23.0 | -8.6 |
| Net margin | -24.2% | -20.3% | -34.8% | -17.4% | -18.0% | -18.0% | -46.0% | -17.5% |
| |
| Basic EPS [+] | ($0.51) | ($0.33) | ($0.40) | ($0.21) | ($0.21) | ($0.21) | ($0.50) | ($0.21) |
| Growth | 56.0% | -18.5% | 91.6% | 1.3% | -58.1% | | 136.2% | 9.6% |
| Diluted EPS [+] | ($0.51) | ($0.33) | ($0.40) | ($0.21) | ($0.21) | ($0.21) | ($0.50) | ($0.21) |
| Growth | 56.0% | -18.5% | 91.6% | 1.3% | -58.1% | | 136.2% | 9.6% |
| |
| Shares outstanding (basic) [+] | 65.3 | 64.6 | 59.4 | 56.5 | 52.2 | 52.2 | 46.2 | 40.6 |
| Growth | 1.2% | 8.8% | 5.0% | 8.3% | 12.9% | | 13.8% | 3.0% |
| Shares outstanding (diluted) [+] | 65.3 | 64.6 | 59.4 | 56.5 | 52.2 | 52.2 | 46.2 | 40.6 |
| Growth | 1.2% | 8.8% | 5.0% | 8.3% | 12.9% | | 13.8% | 3.0% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|